

QIBA PET Tau Biomarker Committee (BC)

Friday, August 11, 2023, at 9 am CT

Call Summary

Notes derived in part from Ms. Matthews' slides

In attendance

Tammie Benzinger, MD, PhD (co-chair)
Dawn Matthews, MS, MBA (co-chair)
Charlie Chen, PhD
Rachid Fahmi, MSc, PhD
Clara Ferreira
Norman Foster, MD

Michael Haas, BSc
Leonardo Iaccarino, PhD
Gregory Klein, PhD
Adriaan Lammertsma, PhD
Antoine Leuzy, PhD
Richard Margolin, MD

Nancy Obuchowski, PhD
Emily Olafson, PhD candidate
John Seibyl, MD
Jean-Luc Vanderheyden, PhD
Dean F. Wong MD, PhD

RSNA Staff

Julie Lisiecki

Discussion topics

- QIBA Transition
- Options for moving forward
- Timeline
- Next steps

QIBA Transition

- New RSNA committee, the Quantitative Imaging Committee (QUIC) will assume oversight of RSNA's quantitative imaging initiatives
- In-process work to be completed **by December 22nd**
- In-process Profiles to be advanced to nearest stage and/or summary or white paper of the Profile to be published
- The QUIC will review future Profiles for inclusion in the QIBA Profile library, (processes TBD)
- QUIC may initially focus on 1-3 QIBs
- Feasible BC deliverables need to be determined for 4-month window
- [QIBA Wiki](#) will continue to be accessible post-transition
- BC members are welcome to submit comments or questions to the [Future Direction of QIBA Activities Form](#)

Options for moving forward

1. Focus only on producing a literature review paper or
 2. Produce a PET Tau Profile within the known timeframe of resource availability – by December 22nd
- BC members unanimously agreed to pursue option 2 and draft a Profile by December
 - Scope of the Profile will be constrained to reasonable expectations
 - Checklist will be similar to the one for PET Amyloid, since scanner methodologies will not change
 - Difference will be in analysis and population selection
 - Need to decide what claim(s) to pursue
 - Task Forces will be developed to review tracers and regions of interest
 - Agreed to avoid pooled tracer analysis due to limited timeframe
 - Will need to consider clinical variability and disease progression
 - Will not be able to address centaur regions due to lack of published data on this topic
 - RSNA staff to aid with creation of a Google form to assist BC member input regarding Profile topics and claims
 - A free form entry to be included for additional thoughts
 - Examples of cross-sectional claims: [SPECT Ioflupane](#) and [Ultrasound Shear Wave Speed](#) (SWS) Profiles
 - **Claim:** specified the quantitation performance (e.g., measurement confidence, detectable change)
 - **Checklist:** specifies the conditions (e.g., equipment, calibration, patient management, process) to achieve the claim performance

Proposed Timeline

- The timeline for Profile completion will be aggressive (below)
- Public Comment must provide enough time for comment, but short enough to complete necessary steps (this is typically 30 days)
- BC considering ways to reach Stage 2 (Consensus) in parallel

	August	September	October	November	December
Decide on plan A (lit review, opt-in) or plan B (tau profile based on amyloid profile)	11-Aug				
Agree on timeline and steps for profile:	11-Aug				
Technical confirmation (in parallel or not changing bc covered by amyloid profile?)		10-Sep			
Plan B1: Longitudinal claim: test-retest literature, Nancy wCV					
Plan B2: Cross sectional claim: ADNI data, Nancy wCV					
Writing: adapting amyloid profile to tau profile			15-Oct		
Writing: Nancy wsCV			15-Oct		
Internal review			31-Oct		
Public comment, consensus stage, comments incorporated				15-Nov	
Final posting and manuscript submission					15-Dec

Proposed revisions to timeline:

Action items	Aug	Sept	Oct	Nov	Dec
Decide on plan A (lit review, opt-in) or plan B (Tau Profile based on Amyloid Profile)	11-Aug				
Agree on timeline and steps for the Profile:	11-Aug				
Consensus in parallel (?) Not sure what this line item means...Stage 2 is near last step (below) ...BC can address feedback as it's received ... this will speed up the entire process		10-Sept			
Plan B1: Longitudinal claim: test-retest literature, Nancy wCV					
Plan B2: Cross sectional claim: ADNI data, Nancy wCV					
Writing: adapting amyloid Profile to Tau Profile		15-Sept			
Writing: Nancy wCV		15-Sept			
Internal review (BC and CC voting, 14 days typically for each; we can do 7 days for each)		30-Sept			
Public comment (30 days needed), comments incorporated as they are received			31-Oct	30-Nov	
Incorporate comments and provide Comment Resolution Spreadsheet to staff					6-Dec
BC and CC voting to advance to Stage 2 (Consensus) (~7 days each)					20-Dec
Final posting and manuscript submission					22-Dec

Next Steps

- Complete literature review and work toward wCV details and claim formulation
- Identify longitudinal use cases

References

QIBA PET Amyloid Profile	QIBA FDG-PET/CT Profile
QIBA SPECT Ioflupane Profile , v2 (example of cross-sectional claim)	
QIBA US SWS Profile (example of cross-sectional claim)	
QIBA LinkedIn page	QIBA Twitter page
QIBA Videos	
Consensus (Stage 2): Comment Resolution Spreadsheet	
Clinically Feasible (Stage 3): Feedback Resolution Spreadsheet	
http://tinyurl.com/QIBA-Public-Comment-Form	

Next Call: Friday, September 8th at 9 am CT {whole group}

08/17	NM Coordinating Ctte – 1 pm CT
09/08	PET Tau BC
10/13	PET Tau BC
11/10	PET Tau BC
12/08	PET Tau BC
12/--	Q4 NM Coordinating Ctte - TBD